Trial · NCT03331835
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 | Baseline to Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24 | Baseline to Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24 | Baseline to Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24 | Baseline to Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change From Baseline at Week 24 in PASI Score | Baseline to Week 24 | The number of analysed participants is not the same as the number of randomised participants, as participants with missing data in all visits for a given endpoint are not included in the mixed model for repeated measurements (MMRM) analysis used to analyse the endpoint. | score on a scale | MEAN |
| SECONDARY | Percent Change From Baseline in PASI Score at Week 24 | Baseline to Week 24 | The number of analysed participants is not the same as the number of randomised participants, as participants with missing data in all visits for a given endpoint are not included in the mixed model for repeated measurements (MMRM) analysis used to analyse the endpoint. | percent change in PASI | MEAN |
| SECONDARY | Change From Baseline at Week 24 in Affected Body Surface Area (BSA) | Baseline to Week 24 | percent change | MEAN | |
| SECONDARY | Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1) | Week 24 | PSI data was missing for many participants at baseline and Week 24. For this reason, no statistical analysis was performed. The data shown is therefore descriptive data. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | PSI Total Score of 0 at Week 24 | Week 24 | PSI data was missing for many participants at baseline and Week 24. For this reason, no statistical analysis was performed. The data shown is therefore descriptive data. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Symptom-free Days From Randomisation to Week 24 | Baseline to Week 24 | PSI data was missing for many participants at baseline and Week 24. For this reason, no statistical analysis was performed. | days | MEAN |
| SECONDARY | Burden of Symptoms | Baseline to Week 24 | Not all participants had recorded PSI data, therefore the analysed number of participants is lower than the randomised number of participants. | score on a scale | MEAN |
| SECONDARY | Change From Baseline at Week 24 in Dermatology Life Quality Index (DLQI) Total Score | Baseline to Week 24 | The number of analysed participants is not the same as the number of randomised participants, as participants with missing data in all visits for a given endpoint are not included in the mixed model for repeated measurements (MMRM) analysis used to analyse the endpoint. | score on a scale | MEAN |
| SECONDARY | DLQI Total Score of 0 or 1 at Week 24 | Week 24 | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Change From Baseline at Week 24 in NAPSI Total Score | Baseline to Week 24 | Only participants with nail involvement at baseline were included in the analysis. Therefore the number of analysed participants differs from the number of randomised participants. | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03331835/outcomes